Health status: What does it mean for payers and patients?

Proceedings of the American Thoracic Society

Volumn 3, Issue 3, 2006, Pages 222-226

  Jones, Paul W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Measurement; Quality of life; Questionnaires

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DETERIORATION; DISEASE ACTIVITY; DYING; HEALTH STATUS; HUMAN; MEDICAL CARE; MEDICAL INSTRUMENTATION; MEDICAL PRACTICE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM;

DISEASE MANAGEMENT; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 33646384402     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200512-126SF     Document Type: Conference Paper

References (23)

1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
2. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jefferies DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
3. Spencer S, Calverley PMA, Burge PS, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-128.
4. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-593.
5. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
6. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:1-5.
7. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
8. Calverley PMA, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
9. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvick A. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. Lancet 2003;361:449-456.
10. Hickey AM, Bury G, O'Boyle CA, Bradley F, O'Kelly FD, Shannon W. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ 1996;313:29-33.
11. O'Boyle CA, McGee H, Hickey A, O'Malley K, Joyce CRB. Individual quality of life in patients undergoing hip replacement. Lancet 1992;339:1088-1091.
12. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-778.
13. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
14. Jones PW, Bosh TK. Changes in quality of life in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-1289.
15. Jarad NA, Wedzicha JA, Burge PS, Calverley PMA. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999;93:161-166.
16. Jones PW, Willits LR, Burge PS, Calverley PMA. Disease severity and the effect of fluticasone proprionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:1-6.
17. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224.
18. Calverley PMA, Spencer S, Willits LR, Burge PS, Jones PW. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003;124:1350-1356.
19. Jones PW. St George's Respiratory Questionnaire: MCID. J Chronic Obstructive Pulmonary Dis 2005;2:75-79.
20. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-415.
21. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 2000;355:362-368.
22. Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt GH, Goldstein RS, White J. Pulmonary rehabilitation for chronic obstructive pulmonary disease (Cochrane Review). Chichester, UK: John Wiley & Sons; 2003.
23. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880-887.